AIM-HI Accelerator Fund

AIM-HI Accelerator Fund Contact information, map and directions, contact form, opening hours, services, ratings, photos, videos and announcements from AIM-HI Accelerator Fund, Nonprofit Organization, 5515 Security Lane, Suite 1105, Rockville, MD.

We provide oncology startups with the resources they need to drive innovative discoveries forward, out of the lab, to the clinics, and eventually to the people battling cancer.

🚀 Congratulations to the 2026 AIM-HI Venture Competition Semi-Finalists!These seven pioneering companies have emerged wi...
06/09/2026

🚀 Congratulations to the 2026 AIM-HI Venture Competition Semi-Finalists!

These seven pioneering companies have emerged with bold ideas and breakthrough technologies aimed at transforming the future of oncology (listed in alphabetical order):
🔹Cellinfinity Bio
🔹Nemea Therapeutics
🔹RedPoint Oncology
🔹Resolute Science
🔹Talus Bio
🔹Trojan Bio
🔹VerImmune

AIM-HI is proud to support visionary scientist-entrepreneurs by connecting them with funding opportunities, expert mentorship, and a global network of oncology innovation leaders accelerating the path from breakthrough science to treatments that reach patients.

Learn more about the competition: https://hubs.ly/Q04kDkYt0

| OncoDaily

🚨 NIH Webinar: A First-in-Class Non-Opioid Therapy for Substance Use Disorders🗓 April 29, 2026 | ⏰ 11:00 AM – 12:00 PM (...
04/21/2026

🚨 NIH Webinar: A First-in-Class Non-Opioid Therapy for Substance Use Disorders

🗓 April 29, 2026 | ⏰ 11:00 AM – 12:00 PM (EST)

Join NIH (NIDA & NCATS) to learn about a novel small molecule targeting the dopamine D3 receptor—designed to block drug reward pathways without addictive liability.

With IND designation secured and a Phase 1 trial upcoming, this approach offers a promising alternative to opioid-based treatments and addresses unmet needs in stimulant and polysubstance use disorders.

💡 Ideal for biotech/pharma leaders, investors, and BD professionals exploring partnership opportunities.

🔗 Register to attend: https://hubs.ly/Q04cZ94l0

Big news from one of our portfolio companies.TellBio's TellDx platform was featured in a new study published in Cancer D...
04/01/2026

Big news from one of our portfolio companies.

TellBio's TellDx platform was featured in a new study published in Cancer Discovery, showing that it can predict how small cell lung cancer patients will respond to a targeted therapy called tarlatamab, using just a blood sample.

For patients with one of the most aggressive forms of lung cancer, that kind of information could change everything about how their care is managed. No invasive tissue biopsy. No guesswork. Just clearer answers, sooner.

This is the kind of science AIM-HI was built to support. Proud to have TellBio in our portfolio.
Full press release here: https://hubs.ly/Q049hR020

The 2026 AIM-HI Venture Competition application deadline is almost here. If you are building an oncology startup with th...
03/14/2026

The 2026 AIM-HI Venture Competition application deadline is almost here. If you are building an oncology startup with the potential to change patient outcomes, now is the time to apply.

AIM-HI is looking for bold innovators advancing the future of cancer research, treatment, and care.

Apply now before the March 15 deadline: https://hubs.ly/Q046Nxrw0

Last chance to apply.The AIM-HI Venture Competitions are closing soon, and this is your final week to submit your applic...
03/09/2026

Last chance to apply.

The AIM-HI Venture Competitions are closing soon, and this is your final week to submit your application. We are looking for the next generation of breakthrough technologies and companies that can transform the future of cancer treatment and patient care.
Apply now: https://hubs.ly/Q0466rbl0

03/02/2026

Only TWO WEEKS left to apply for the AIM-HI Venture Competitions. Don’t miss your chance to accelerate your idea, get funding, and join a community driving real impact. Apply now: https://hubs.ly/Q045fG7k0

Portfolio Update: Privo TechnologiesPrivo has completed its Phase 1/2 study of PRV211, a first-in-class intraoperative c...
02/19/2026

Portfolio Update: Privo Technologies

Privo has completed its Phase 1/2 study of PRV211, a first-in-class intraoperative chemotherapy patch for head and neck cancer.

Results showed:
• Zero treatment-related serious adverse events
• No systemic toxicities
• Normal wound healing
• Targeted delivery with negligible systemic absorption

PRV211 is applied directly to the tumor bed during surgery to help reduce recurrence risk.

Innovations like this are exactly what AIM-HI is built to accelerate.

Read the full release: https://hubs.ly/Q043TmRW0

Less than ONE month left.The 2026 AIM-HI Venture Competition closes March 15.If you are building a breakthrough in oncol...
02/17/2026

Less than ONE month left.

The 2026 AIM-HI Venture Competition closes March 15.

If you are building a breakthrough in oncology, this is your opportunity to access seed funding, expert feedback, and potential follow-on investment.

Apply now: https://hubs.ly/Q043rScY0

Calling oncology founders.Applications are now open for the 2026 AIM-HI Venture Competition.If you are building a breakt...
02/12/2026

Calling oncology founders.

Applications are now open for the 2026 AIM-HI Venture Competition.

If you are building a breakthrough cancer therapy or technology and need non-dilutive funding, strategic mentorship, and access to a global network of investors and experts, this is your opportunity.

AIM-HI was created to bridge the gap between discovery and delivery. We accelerate bold science out of the lab and toward patients.

Apply now and take the next step in transforming cancer treatment.
https://hubs.ly/Q042WvrD0

Address

5515 Security Lane, Suite 1105
Rockville, MD
20852

Website

,

Alerts

Be the first to know and let us send you an email when AIM-HI Accelerator Fund posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Organization

Send a message to AIM-HI Accelerator Fund:

Shortcuts

Share

Category